Compare BioNano Genomics Inc (BNGO) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Wells Fargo & Co — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Wells Fargo & Co trades at $85.94 (market cap $258.30B). The key difference: Wells Fargo & Co is far larger — about 19568.2× BioNano Genomics Inc's market cap, and Wells Fargo & Co pays a 2.11% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | WFC | |
|---|---|---|
Market Cap | $13.20M | $258.30B |
Sector | Health | Financials |
52-Week High | $4.92 | $96.40 |
52-Week Low | $1.09 | $73.42 |
Enterprise Value | $15.81M | — |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Wells Fargo (WFC) trades at $87.70, up 0.67% with a bullish technical outlook. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $2.00 versus $1.73 expected, driven by net interest income and fee growth. Revenue trends upward from $83.7B in 2025 to projected $85.0B in 2026, while net income margin remains robust at 25.5%. Recent news highlights the bank's $1B+ technology investment in AI tools for wealth management and a healthy investment banking pipeline.
The outlook is positive with a consensus price target of $99.10 offering 13% upside. Key opportunities include continued earnings momentum and efficiency gains from tech investments. Risks involve expense pressures, macroeconomic sensitivity, and competitive banking sector dynamics. Analyst sentiment is mixed with 45% buy ratings but near-term execution on guidance will be critical for sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
